Dapagliflozin in triple therapy for treating type 2 diabetes

Information for the public Published: 23 November 2016

www.nice.org.uk

What has NICE said?

Dapagliflozin (Forxiga) is recommended for treating type 2 diabetes as part of triple therapy with metformin and a sulfonylurea.

What does this mean for me?

If you have type 2 diabetes that is not adequately controlled with metformin and a sulfonylurea, and your doctor thinks that dapagliflozin is the right treatment, you should be able to have the treatment on the NHS.

If you are not eligible for treatment as described above you should be able to continue taking dapagliflozin until you and your doctor decide it is the right time to stop.

The condition and the treatment

In diabetes the amount of glucose (sugar) in the blood is too high, which can lead to serious health problems. Type 2 diabetes occurs when the body can't make enough insulin

(a hormone made by the body to control the level of sugar in the blood), or when it can't use the insulin it produces properly.

Dapagliflozin works by blocking re-absorption of blood sugar by the kidneys, increasing the amount of sugar removed from the body in the urine. This reduces the amount of sugar in the blood.

<u>NHS Choices</u> may be a good place to find out more.

These organisations can give you advice and support:

- <u>Diabetes UK</u>, 0345 123 2399
- Diabetes Research & Wellness Foundation, 0239 263 7808
- Black and Ethnic Minority Diabetes Association (BEMDA), 0207 723 5357
- <u>Surya Foundation</u>, 0208 398 9292

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-2169-0

Accreditation

